{"product_id":"slp-pestle-analysis","title":"(SLP) Simulations Plus, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Simulations Plus, Inc. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why they matter for strategy and investment. The page includes a real preview\/sample of the report so you can judge style and depth; purchase the full version to get the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA MIDD support for in-silico models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA’s MIDD push keeps in-silico tools central to drug filings, and that supports demand for Simulations Plus products like GastroPlus, PKPlus, and its QSP suite. When regulators accept PBPK and model-informed evidence, validated models gain more value because they must hold up in review, not just in research. That makes regulatory-grade software a bigger part of the drug development stack, not a niche add-on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal regulator demand for faster trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUS FDA, EMA, MHRA, and PMDA all push faster, model-informed development, so software that cuts animal use, predicts exposure, and supports earlier dose selection has a clear policy tailwind. Simulations Plus sells to multinational sponsors that must satisfy 4 agency rule sets at once, which raises demand for consistent simulation tools. That makes regulatory speed a direct growth driver for the Company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic biomedical research funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eU.S. biomedical research funding matters for Simulations Plus, Inc. because NIH spent about $47 billion in FY2024, and that money feeds academic and translational drug projects that need modeling and simulation tools. When public funding rises, more preclinical and early clinical work moves forward, which can lift demand for Simulations Plus, Inc. software and consulting. If budgets tighten, research starts can slow and pipeline demand can soften.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-border pharma policy and trade risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSimulations Plus sells into many countries, so tariff shifts, sanctions, and geopolitical stress can slow pharma IT spending and delay drug programs. The WTO forecast world merchandise trade growth at 2.6% in 2024 and 3.3% in 2025, showing how policy swings can filter into customer budgets and timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal policy shocks can delay projects\u003c\/li\u003e\n\u003cli\u003eTrade friction can cut client spending\u003c\/li\u003e\n\u003cli\u003eDiversified regions help reduce risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDrug developers often pause cross-border work when supply chains or data rules get less clear. For Simulations Plus, wider geographic exposure helps balance weakness in any one market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare cost-containment pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolicy pressure to cut drug R\u0026amp;D time and cost stays high in the US, EU, and Japan, where late-stage trial failures still waste hundreds of millions per program. With overall clinical success rates near 10% and Phase III costs often above $20 million, sponsors now need stronger proof of probability of success before moving into expensive trials, which supports Simulations Plus, Inc.'s predictive software and consulting work.\u003c\/p\u003e\n\u003cp\u003eFor Simulations Plus, Inc., that backdrop is favorable because regulators and payers keep pushing for better modeling, fewer animal studies, and smarter trial design. In FY2025, the company reported $75.1 million in revenue, showing demand for tools that help cut development risk and improve go-no-go decisions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh policy pressure to reduce R\u0026amp;D waste\u003c\/li\u003e\n\u003cli\u003eBetter success odds needed before Phase III\u003c\/li\u003e\n\u003cli\u003eModeling and consulting fit cost-containment goals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy Tailwinds Boost Simulations Plus Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical policy is supportive for Simulations Plus, Inc. as FDA, EMA, MHRA, and PMDA keep pushing model-informed drug development, which raises demand for validated simulation software. U.S. NIH funding was about $47 billion in FY2024, and that helps feed early-stage programs that use these tools. FY2025 revenue was $75.1 million, showing the policy tailwind is real.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding\u003c\/td\u003e\n\u003ctd\u003e$47B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSimulations Plus revenue\u003c\/td\u003e\n\u003ctd\u003e$75.1M FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExamines how Political, Economic, Social, Technological, Environmental, and Legal forces shape Simulations Plus, Inc.’s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Simulations Plus PESTLE summary that quickly highlights external risks and opportunities for easier planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources linking each key claim to traceable industry reports, government data, and benchmarks to speed due diligence and boost model credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma R\u0026amp;D budget tightening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigher financing costs and tighter capital allocation are keeping biopharma R\u0026amp;D budgets under pressure. That pushes drug makers to cut failed experiments and use simulation tools earlier in development. For Simulations Plus, Inc., this supports demand for software that can lower trial-and-error spend and improve decision quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech funding cycle exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSimulations Plus, Inc. is exposed to biotech funding cycles because many customers rely on venture rounds and public-market access to pay for software and services. In 2024, global biotech financing stayed below 2021 peaks, with venture deal values still under pressure, which can delay renewals and push out new projects. When capital returns, model-driven work can ramp fast as funded biotechs add more simulation use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutsourcing of modeling work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharma companies are still pushing pharmacometrics and regulatory modeling work to outside specialists to keep fixed headcount low. That helps Simulations Plus sell more consulting, training, and contract research, not just software seats. It also makes Company Name look like a partner in drug development decisions, which can deepen client ties and lift recurring work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal client mix and FX risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSimulations Plus, Inc. sells across North America, Europe, and other regions, so FX moves can change reported revenue even when local demand is flat. A stronger U.S. dollar can trim non-US sales in dollar terms, while a weaker dollar can lift them. That makes a broad client base a growth buffer and a currency risk at the same time.\u003c\/p\u003e\n\u003cp\u003eCurrency swings matter most when overseas revenue is meaningful, because translation changes can hit margins and guidance. In the latest filing cycle, the company still relied on a diversified international customer base, so FX can shift quarterly results without changing the underlying pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal sales reduce demand concentration.\u003c\/li\u003e\n\u003cli\u003eFX can distort reported revenue.\u003c\/li\u003e\n\u003cli\u003eNon-US wins may not translate evenly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRecurring software and services revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSimulations Plus, Inc. sells software licenses alongside consulting and training, so its recurring software base gives better cash-flow visibility than services alone. The risk is that consulting demand is more exposed to project delays and client budget cuts, and economic slowdowns usually hit discretionary services before core software maintenance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring licenses support revenue visibility.\u003c\/li\u003e\n\u003cli\u003eConsulting is more cyclical.\u003c\/li\u003e\n\u003cli\u003eBudget cuts can delay projects fast.\u003c\/li\u003e\n\u003cli\u003eMaintenance is steadier than training.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigher Rates and Weak Biotech Funding Press Simulations Plus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher rates and cautious biopharma spending still matter for Simulations Plus, Inc.; its fiscal 2024 revenue was about $60 million, so even small delays in software or consulting deals can move results. Venture funding for biotech also stayed below the 2021 peak in 2025, which can slow new customer starts, while a stronger U.S. dollar can trim overseas sales. Recurring software helps cushion the cycle, but services stay more exposed to budget cuts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eEconomic factor\u003c\/th\u003e\n\u003cth\u003eLatest signal\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest rates\u003c\/td\u003e\n\u003ctd\u003eStill restrictive in 2025\u003c\/td\u003e\n\u003ctd\u003ePressures biotech budgets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech funding\u003c\/td\u003e\n\u003ctd\u003eBelow 2021 peak in 2025\u003c\/td\u003e\n\u003ctd\u003eDelays new sales and renewals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX\u003c\/td\u003e\n\u003ctd\u003eUSD strength hurts translation\u003c\/td\u003e\n\u003ctd\u003eCan cut reported overseas revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue mix\u003c\/td\u003e\n\u003ctd\u003eAbout $60 million in FY2024\u003c\/td\u003e\n\u003ctd\u003eRecurring software softens cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSimulations Plus, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Simulations Plus, Inc. PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging population and chronic disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy 2050, 1 in 6 people worldwide will be over 65, and WHO says noncommunicable diseases still cause about 74% of global deaths. That pushes demand for oncology, cardiometabolic, neurodegeneration, and pulmonary drugs, so Simulations Plus, Inc. needs better dose prediction and safer development paths. Disease-specific QSP models become more valuable as patient mix gets older and more complex.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for safer faster drug development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients, clinicians, and advocacy groups now expect safer, faster drug development, especially since about 90% of drug candidates still fail in clinical trials. That social pressure pushes drug makers to predict risk before first-in-human studies. For Simulations Plus, simulation-based workflows help cut uncertainty early and can reduce late-stage waste.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShortage of pharmacometric talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe talent pool for pharmacokinetics, pharmacometrics, and systems pharmacology stays thin, so many drug sponsors still buy outside training and consulting to build in-house skills. That keeps demand for Simulations Plus’s expert services high, not just its software, because model-informed drug development and regulatory work need scarce specialists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHybrid scientific collaboration norms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLife-science work is now often split across time zones and hybrid teams, so Simulations Plus, Inc. benefits from cloud-based tools that make model sharing, review, and training easier. The company’s consulting and software model fits this shift because remote delivery lowers friction for global clients and faster project handoffs. Hybrid norms also favor platforms that support on-demand learning, which matters as regulated teams need consistent use across sites.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHybrid teams need cloud access\u003c\/li\u003e\n\u003cli\u003eGlobal support fits remote delivery\u003c\/li\u003e\n\u003cli\u003eTraining tools improve adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrust and explainability in AI tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn regulated sciences, trust depends on interpretability and traceability, so black-box AI is harder to defend in discovery and submission work. Simulations Plus is better placed when AI outputs are tied to mechanistic models and clear assumptions, because that makes review, audit, and regulator questions easier to answer.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInterpretable outputs support audit trails.\u003c\/li\u003e\n\u003cli\u003eBlack-box models raise defense risk.\u003c\/li\u003e\n\u003cli\u003eMechanistic pairing improves trust.\u003c\/li\u003e\n\u003cli\u003eTransparent assumptions aid submissions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSafer drug design gains urgency as aging, chronic disease rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOlder, sicker populations raise demand for safer model-led drug design; WHO says noncommunicable diseases cause about 74% of deaths, and 1 in 6 people will be over 65 by 2050. With about 90% of drug candidates failing in trials, sponsors want clearer, earlier risk checks. Simulations Plus, Inc. benefits from that shift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal NCD deaths\u003c\/td\u003e\n\u003ctd\u003e74%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug candidate failure\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePopulation 65+ by 2050\u003c\/td\u003e\n\u003ctd\u003e1 in 6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI and ML in ADMET prediction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSimulations Plus, Inc. uses AI and machine learning to predict ADMET traits from molecular structure, and ADMET Predictor helps cut early screening time versus lab-first workflows. In fiscal 2025, the company kept investing in software that supports faster virtual screening and broader early-discovery use cases. As ML gets better, throughput rises and more compounds can be ranked before costly wet-lab work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQSP and PBPK model complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQSP and PBPK modeling are math-heavy, so Simulations Plus competes on model accuracy, calibration, and ease of use. The Company has 5 named tools in this area: DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym.\u003c\/p\u003e\n\u003cp\u003eThat breadth matters because drug teams need models that fit real biology and run reliably across many scenarios. In FY2025 and FY2026, buyers still pay for tools that cut rework and improve decision speed.\u003c\/p\u003e\n\u003cp\u003eSo, technical depth is a moat only if the models stay validated and usable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCloud and HPC model scaling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge simulation runs now depend on HPC and cloud scale, letting Simulations Plus, Inc. run more scenarios, bigger parameter sweeps, and faster optimization cycles. That makes software speed, parallel processing, and cloud compatibility key buying factors. If the platform lags, model runs slow and client workflows stall.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInteroperability with regulatory datasets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor Simulations Plus, Inc., interoperability with regulatory datasets matters because drug teams must move assay, clinical, and submission data across systems without rekeying. The FDA still uses eCTD (electronic common technical document) for structured submissions, so software that maps cleanly into it can cut manual transfer errors and speed review-ready analysis.\u003c\/p\u003e\n\u003cp\u003eThat is especially useful for sponsors running separate platforms for preclinical, clinical, and regulatory work, where even small data mismatches can delay decisions. Better data links also support faster batch analysis across larger study sets and make audit trails easier to maintain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConnects assay, clinical, and filing data\u003c\/li\u003e\n\u003cli\u003eReduces manual errors and rework\u003c\/li\u003e\n\u003cli\u003eSpeeds analysis across internal systems\u003c\/li\u003e\n\u003cli\u003eHelps meet eCTD submission needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCybersecurity for scientific software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScientific software at Simulations Plus, Inc. now stores sensitive compound, model, and clinical data, so access control, encryption, and audit trails are no longer optional. IBM’s 2024 Cost of a Data Breach report put the global average breach cost at $4.88 million, and one incident can also stall regulated submissions and shake client trust. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtect proprietary data with strict role-based access.\u003c\/li\u003e\n\u003cli\u003eEncrypt data in transit and at rest.\u003c\/li\u003e\n\u003cli\u003eKeep full logs for regulated audits.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSimulations Plus: AI, Cloud, and Security Power Its Edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTechnological strength is central for Simulations Plus, Inc.: AI\/ML speeds ADMET screening, QSP\/PBPK tools stay valuable only if validated, and cloud\/HPC support faster runs. In fiscal 2025, the Company kept investing in workflow speed, data links, and secure handling of sensitive model data.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI\/ML\u003c\/td\u003e\n\u003ctd\u003eFaster compound ranking\u003c\/td\u003e\n\u003ctd\u003eADMET Predictor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud\/HPC\u003c\/td\u003e\n\u003ctd\u003eMore scenarios, faster runs\u003c\/td\u003e\n\u003ctd\u003eParallel scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecurity\u003c\/td\u003e\n\u003ctd\u003eProtect client data\u003c\/td\u003e\n\u003ctd\u003e$4.88M avg breach cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and EMA validation expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA and EMA expect submission software to be credible, traceable, and fit for purpose, so Simulations Plus must keep each model documented, versioned, and backed by evidence. In 2025, that means validation has to stay current across its core platforms, not just at launch. If a model cannot be audited end to end, it can delay filings and weaken customer trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIPAA and GDPR data privacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSimulations Plus, Inc.’s consulting and clinical-pharmacology work can involve protected health information, so HIPAA controls matter for storage, access, and retention. GDPR can be even harsher: fines can reach €20 million or 4% of global annual turnover, and EU personal data transfer rules can slow client projects. That means internal systems and client workflows need tight consent, deletion, and cross-border transfer controls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftware IP and trade secrets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSimulations Plus, Inc.’s value rests on proprietary algorithms, model libraries, and source code, so copyright, trade secret, and patent protection are central to its moat. Its FY2025 Form 10-K shows that protecting this IP is tied to revenue durability, since software and services are sold through licenses and contracts. Global license terms need tight control, because weak usage rules can leak know-how or limit enforcement across clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConsulting liability and contract terms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory consulting and contract research can create liability if a model or analysis is seen as incomplete or misleading, especially when it supports filing decisions. For Simulations Plus, Inc., tight scope limits, indemnity, and limitation-of-liability terms matter because one disputed deliverable can affect both client claims and future work.\u003c\/p\u003e\n\u003cp\u003eStrong records help too: version control, assumptions, and sign-off logs make it easier to defend results used in submissions. Clear contract terms and audit-ready documentation cut dispute risk and keep exposure tied to the fee at stake, not the downstream regulatory outcome.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse clear scope and deliverables.\u003c\/li\u003e\n\u003cli\u003eCap liability and define indemnity.\u003c\/li\u003e\n\u003cli\u003eKeep full analysis and sign-off logs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExport controls and sanctions screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSimulations Plus, Inc. must screen customers, end users, and destinations against export-control and sanctions lists, since its software and consulting can serve multinational pharma and research groups. A missed match can trigger blocked sales, fines, and contract delays, plus reputational damage with regulated clients. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScreen every customer and destination.\u003c\/li\u003e\n\u003cli\u003eCheck sanctions before each sale.\u003c\/li\u003e\n\u003cli\u003eControl risk in global pharma deals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSimulations Plus Faces High-Stakes Legal and Compliance Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSimulations Plus, Inc. faces tight legal rules on validation, privacy, IP, liability, and trade controls. FDA and EMA filings need traceable models, while GDPR fines can reach €20 million or 4% of global turnover. Strong contracts, audit logs, and license controls help protect its FY2025 software and consulting revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal risk\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR penalty\u003c\/td\u003e\n\u003ctd\u003e€20 million or 4% turnover\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuditability\u003c\/td\u003e\n\u003ctd\u003eEnd-to-end traceability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimal testing reduction and NAMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNon-animal methods are gaining ground across drug development, and in-silico models support the 3Rs by reducing, refining, and replacing animal studies where possible. That makes Simulations Plus software relevant as regulators and pharma teams add NAMs (new approach methods) to safety packages and model-informed decisions, while ethical pressure on animal use keeps rising.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower lab waste through simulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSimulation can cut wet-lab loops, chemical use, and failed runs, which lowers solvent, plastic, and biohazard waste. In pharma, only about 1 in 10 drug candidates reaches approval, so reducing dead-end studies can materially shrink disposal volumes. That makes Simulations Plus, Inc. useful for clients trying to run greener R\u0026amp;D with less environmental burden.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClimate-related disease modeling demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClimate change is increasing demand for models that link weather, exposure, and disease. WHO has warned that climate change can add about 250,000 extra deaths a year from 2030 to 2050, while heat-related illness and respiratory stress are already rising. That makes Simulations Plus, Inc. tools like DILIsym more relevant for predicting toxicity, metabolism, and organ-specific risk in drug and chemical safety. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eESG reporting from life-science clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge pharma and biotech buyers are under rising ESG reporting pressure, so they favor tools that can help cut animal use, trim experiment counts, and reduce travel-linked emissions. For Simulations Plus, that makes software value part of the client’s sustainability story, not just an R\u0026amp;D tool. In procurement, that can tilt vendor choice toward platforms that support greener workflows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eESG goals now shape vendor picks\u003c\/li\u003e\n\u003cli\u003eFewer animals supports compliance stories\u003c\/li\u003e\n\u003cli\u003eLess travel can lower Scope 3 emissions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnergy use from cloud and compute\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced simulation and AI workloads need far more compute and power, so cloud modeling now has a real energy cost. The IEA said global data-center electricity use was about 460 TWh in 2022 and could more than double by 2026, which makes energy use a clear operating and sustainability issue for Simulations Plus, Inc.\u003c\/p\u003e\n\u003cp\u003eFor Simulations Plus, Inc., efficient code and leaner workflows matter because every extra run adds cloud cost and emissions. Selective scenario testing, smaller model batches, and better use of high-performance compute can cut wasted cycles and help keep cloud intensity down. One clean run is cheaper than ten noisy ones.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore AI use means more electricity demand.\u003c\/li\u003e\n\u003cli\u003eCloud cost rises with run volume.\u003c\/li\u003e\n\u003cli\u003eEfficient code lowers energy intensity.\u003c\/li\u003e\n\u003cli\u003eSelective runs reduce wasted compute.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreen Pharma Rules Boost Simulations Plus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvironmental pressure is helping Simulations Plus, Inc. because pharma buyers want fewer animal tests, less waste, and lower Scope 3 emissions. IEA data showed data-center electricity use at about 460 TWh in 2022, and it could more than double by 2026, so energy-efficient cloud modeling matters too. Climate-linked toxicity and exposure risks also make simulation tools more relevant.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal testing\u003c\/td\u003e\n\u003ctd\u003eMore NAMs adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWaste\u003c\/td\u003e\n\u003ctd\u003eFewer wet-lab runs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompute energy\u003c\/td\u003e\n\u003ctd\u003e460 TWh in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClimate risk\u003c\/td\u003e\n\u003ctd\u003eRising toxicity modeling need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234951766281,"sku":"slp-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/slp-pestle-analysis.webp?v=1785731844","url":"https:\/\/dcfanalyst.com\/products\/slp-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}